A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

The NSW Government will offer nirsevimab, a type of monoclonal antibody immunisation to: Infants at birth not protected by maternal RSV vaccination; Infants at birth with certain medical conditions ...

As the first healthcare institution in Southeast Asia to introduce and provide the Monoclonal Antibody against RSV, Nirsevimab, for all infants, this initiative marks a significant advancement in ...

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.It will mean all newborn ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.